Generali Investments Management Co LLC Purchases 65,552 Shares of Pfizer Inc. $PFE

Key Points

• Generali Investments Management Co LLC increased its stake in Pfizer by 84.5% in Q4, buying 65,552 shares to hold 143,144 shares worth about $3.56 million.
• Pfizer declared a quarterly dividend of $0.43 (ex-dividend May 8, payable June 12), implying a $1.72 annualized payout and a 6.4% yield with a payout ratio of 126.47%.
• Pfizer beat Q4 estimates with EPS of $0.66 vs. $0.57 consensus and revenue of $17.56B (down 1.2% YoY); the street’s average rating is "Hold" with an average target of $28.48.

Generali Investments Management Co LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 84.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 143,144 shares of the biopharmaceutical company's stock after purchasing an additional 65,552 shares during the quarter. Generali Investments Management Co LLC's holdings in Pfizer were worth $3,564,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Northern Trust Corp raised its holdings in Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Pfizer by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock worth $1,255,860,000 after purchasing an additional 897,786 shares during the last quarter. Legal & General Group Plc raised its holdings in Pfizer by 8.6% during the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares during the last quarter. Finally, Amundi raised its holdings in Pfizer by 10.8% during the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company's stock worth $1,096,380,000 after purchasing an additional 4,043,413 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of PFE opened at $27.01 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a 50 day simple moving average of $27.23 and a 200 day simple moving average of $26.06. Pfizer Inc. has a 52-week low of $21.97 and a 52-week high of $28.75. The firm has a market capitalization of $153.56 billion, a PE ratio of 19.86 and a beta of 0.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the firm earned $0.63 EPS. Pfizer's quarterly revenue was down 1.2% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer's payout ratio is currently 126.47%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; ex-div May 8), reinforcing Pfizer’s long track record of income (350th consecutive quarterly dividend) and supporting demand from income-minded investors. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Seagen acquisition appears to be contributing to growth and a stronger oncology franchise (Antibody‑Drug Conjugates), supporting medium-term revenue upside as Pfizer expands cancer capabilities. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: GLP‑1 obesity program momentum — Phase 2b monthly GLP‑1 data and plans for a large clinical program provide optionality beyond legacy drugs and could open a new growth engine if later‑stage trials succeed. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Positive Sentiment: Multiple early‑stage pipeline advances (completion of a China Phase 1 for a heart‑failure candidate, new gastric‑emptying study for an obesity asset, new Phase 1 cancer and liver studies) add cadence and long‑term upside to the pipeline. Pfizer Advances Early-Stage Heart Failure Candidate With Completion Of Chinese Phase 1 Study
• Neutral Sentiment: Pfizer released results from its 2026 shareholder meeting — largely procedural items that don’t materially change near‑term fundamentals. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Bristol Myers and Pfizer will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27 — improves patient access but raises questions about pricing/volume tradeoffs; watch margin impact. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
• Neutral Sentiment: Broader industry news — competitors (e.g., Eli Lilly, Novo Nordisk) continue to shape the obesity/GLP‑1 landscape; this is both competitive risk and market validation for Pfizer’s obesity push. Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
• Negative Sentiment: Pfizer ended a Phase 1 cancer trial, trimming part of its oncology pipeline — a reminder that not all program investments convert to later‑stage value and a near‑term negative headline. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism persists (Barclays remains negative; consensus leans to “hold”), which can cap upside until clearer revenue/cost trajectories emerge. Barclays Remains a Sell on Pfizer (PFE)

Analysts Set New Price Targets

A number of brokerages have recently commented on PFE. Argus raised Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price target for the company in a research note on Monday, March 2nd. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. UBS Group boosted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Monday, April 13th. HSBC boosted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, March 17th. Finally, Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They set an "underweight" rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, Pfizer presently has an average rating of "Hold" and an average target price of $28.48.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.